Section Arrow
Quote
CELZ.NASDAQ
- Creative Medical Technology Holdings
Quotes are at least 15-min delayed:2026/05/23 15:11 EDT
Regular Hours
Last
 2.39
+0.09 (+3.91%)
Day High 
2.395 
Prev. Close
2.3 
1-M High
2.4 
Volume 
47.69K 
Bid
2.34
Ask
2.35
Day Low
2.32 
Open
2.32 
1-M Low
2.08 
Market Cap 
8.50M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 2.25 
20-SMA 2.24 
50-SMA 2.14 
52-W High 6.25 
52-W Low 1.504 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.07/-1.51
Enterprise Value
8.50M
Balance Sheet
Book Value Per Share
1.65
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
88.60K
Operating Revenue Per Share
0.02
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
GOVXGeoVax Labs Inc.3.64+0.89+32.36%-- 
MTVAMetaVia Inc.3.85+0.98+34.15%-- 
AKTXAkari Therapeutics Plc18.27+13.13+255.45%-- 
LIMNLiminatus Pharma Inc0.1694-0.0766-31.14%-- 
IOVAIovance Biotherapeutics4.11+0.41+11.08%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.